TransMedics Group/$TMDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About TransMedics Group
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Ticker
$TMDX
Sector
Health
Primary listing
Employees
728
Headquarters
Website
TMDX Metrics
BasicAdvanced
$4B
57.51
$2.02
2.05
-
Price and volume
Market cap
$4B
Beta
2.05
52-week high
$177.37
52-week low
$55.00
Average daily volume
1.1M
Financial strength
Current ratio
9.857
Quick ratio
8.927
Long term debt to equity
162.15
Total debt to equity
163.1
Interest coverage (TTM)
5.42%
Profitability
EBITDA (TTM)
100.302
Gross margin (TTM)
59.79%
Net profit margin (TTM)
13.49%
Operating margin (TTM)
14.41%
Effective tax rate (TTM)
3.28%
Revenue per employee (TTM)
$730,000
Management effectiveness
Return on assets (TTM)
5.80%
Return on equity (TTM)
28.21%
Valuation
Price to earnings (TTM)
57.508
Price to revenue (TTM)
7.354
Price to book
12.42
Price to tangible book (TTM)
13.29
Price to free cash flow (TTM)
225.177
Free cash flow yield (TTM)
0.44%
Free cash flow per share (TTM)
0.515
Growth
Revenue change (TTM)
48.09%
Earnings per share change (TTM)
2,163.11%
3-year revenue growth (CAGR)
117.78%
3-year earnings per share growth (CAGR)
5.61%
What the Analysts think about TMDX
Analyst ratings (Buy, Hold, Sell) for TransMedics Group stock.
Bulls say / Bears say
TransMedics Group reported a 159% year-over-year increase in Q3 2023 revenues, reaching $66.4 million, surpassing the consensus estimate of $49.19 million. This growth was primarily driven by increased utilization of the company's Organ Care System (OCS) across all three products and the addition of logistics and aviation revenue. (Benzinga)
The company raised its full-year 2023 revenue guidance to a range of $222 million to $230 million, up from the previous guidance of $180 million to $190 million, indicating strong business momentum and confidence in future performance. (Benzinga)
Analysts have shown optimism towards TransMedics, with Oppenheimer raising the price target to $130.00 and maintaining an 'outperform' rating, reflecting positive expectations for the company's stock performance. (Defense World)
In October 2024, TransMedics reported Q3 earnings of $0.12 per share, missing the consensus estimate of $0.28, and revenues of $108.76 million, which were below expectations, leading to concerns about the company's financial performance. (Nasdaq)
On February 14, 2025, Bleichmar Fonti & Auld LLP announced an investigation into TransMedics for potential violations of federal securities laws, following a 30% stock drop, raising concerns about legal and regulatory challenges. (GlobeNewswire)
The company's Q3 2023 gross margin declined to 61% from 71% a year ago, impacted by transition initiatives following the Summit Aviation acquisition and inefficiencies in transitioning out of its legacy charter business, which may affect profitability. (Benzinga)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
TMDX Financial Performance
Revenues and expenses
TMDX Earnings Performance
Company profitability
TMDX News
AllArticlesVideos
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Reach Out
Accesswire·2 months ago
Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities Investigation
Accesswire·2 months ago
Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May
MarketBeat·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for TransMedics Group stock?
TransMedics Group (TMDX) has a market cap of $4B as of August 08, 2025.
What is the P/E ratio for TransMedics Group stock?
The price to earnings (P/E) ratio for TransMedics Group (TMDX) stock is 57.51 as of August 08, 2025.
Does TransMedics Group stock pay dividends?
No, TransMedics Group (TMDX) stock does not pay dividends to its shareholders as of August 08, 2025.
When is the next TransMedics Group dividend payment date?
TransMedics Group (TMDX) stock does not pay dividends to its shareholders.
What is the beta indicator for TransMedics Group?
TransMedics Group (TMDX) has a beta rating of 2.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.